Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-TLX250 PET/CT in Renal Masses
NCT05861778Phase 1Completed
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Jun 2023
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 89Zr-DFO-girentuximab in clear cell renal cell carcinoma (ccRCC), sponsored by Telix Pharmaceuticals Limited. Primary endpoints: Safety parameter Physical Examination at 9 days, Safety parameter Vital Signs at 9 days and 3 more. Started Jun 2023; status: completed.
02
Drugs
89Zr-DFO-girentuximab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05861778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861778.